Inter- and intra-observer variability of ultrasonographic arm muscle thickness measurement by critical care physicians

Bedside assessment of sarcopenia in hospitalized patients with liver cirrhosis: Magnitude and clinical implications

BACKGROUND

Sarcopenia is associated with many adverse outcomes in patients with cirrhosis. The tools currently in use for assessing sarcopenia have numerous flaws. We evaluated the utility of portable ultrasonography and a dynamometer for the bedside assessment of sarcopenia and its implications in hospitalized cirrhosis patients.

METHODS

A dynamometer was used to test the hand-grip strength (HGS) and ultrasound was used to measure the thickness of the forearm and quadriceps muscles. HGS value < 27 kg for men and < 16 kg for women was taken as significant according to the European Working Group on Sarcopenia in Older People (EWGSOP2) criteria. The lower normal limit of muscle mass (5th percentile) was determined on 100 matched healthy controls.

RESULTS

According to the EWGSOP2 criteria and HGS values, the prevalence of sarcopenia and probable sarcopenia among 300 cirrhosis patients were 56% and 62.3%, respectively. HGS alone identified sarcopenia in 88.9% of patients, while overestimated it in 6.3% of cases. The prevalence rate of sarcopenic obesity was 11%. Compared to patients without sarcopenia, sarcopenic patients had more complications of cirrhosis such as ascites, variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis, sepsis, hepatorenal syndrome and refractory ascites. In-hospital (p = 0.037), three-month (p < 0.001), and six-month (p < 0.001) mortality rates were all higher among sarcopenic patients. On cox regression survival analysis, overall six-month mortality was significantly higher in sarcopenic patients compared to patients without sarcopenia (hazard ratio, 6.37; 95% confidence interval, 3.15-12.8, p < 0.001).

CONCLUSION

Bedside assessment of sarcopenia using a portable ultrasound machine and a dynamometer detects liver cirrhosis patients with high risk of complications and mortality.

Impact of Muscle Changes Assessed by Ultrasonography on Muscle Strength and Functioning after ICU Discharge: A Systematic Review with Meta-Analysis

BACKGROUND

Ultrasonography has been used to identify structural, quantitative, and qualitative muscle changes. These changes have been assessed in different muscles during ICU stays; however, it is unclear if it can predict functioning after ICU discharge.

OBJECTIVE

To analyze the relationship between muscle changes assessed by ultrasonography and the strength and functioning of ICU survivors.

METHODS

A systematic review with a meta-analysis was performed according to the MOOSE guidelines and registered in PROSPERO. Searches of the following databases were performed by two of the authors: PubMed, Cinahl, Embase, Scopus, LILACS, Web of Science, and Science Direct. Qualitative analysis was performed using NOS and AHRQ scales. Meta-analysis was performed using the "R", "metafor" package. Heterogeneity was assessed by I2 and Cochran's Q test. Meta-regression analyses were performed to verify the moderators, and funnel plots and Egger's regression intercept test were used to analyze the publication bias.

RESULTS

Sixteen articles were included in the qualitative assessment, and nine were used in the quantitative assessment. There is evidence of correlations between MT and muscle strength (r = 0.20 [0.11; 0.27]; p < 0.0001), and MT (r = 0.35 [0.19; 0.49]; p < 0.0001), CSA (r = 0.30 [0.10; 0.47]; p = 0.0038), EI (r = -0.29 [-0.53; -0.01]; p = 0.043) and mobility. In the subgroup analyses, some evidence of a correlation between specific muscles and strength and mobility were found.

CONCLUSIONS

There is evidence for the correlation between muscle characteristics assessed by US and functioning outcomes.

Ultrasonographic examination of masticatory muscles in patients with TMJ arthralgia and headache attributed to temporomandibular disorders

This study used ultrasonography to compare the thickness and cross-sectional area of the masticatory muscles in patients with temporomandibular joint arthralgia and investigated the differences according to sex and the co-occurrence of headache attributed to temporomandibular disorders (HATMD). The observational study comprised 100 consecutive patients with TMJ arthralgia (71 females and 29 males; mean age, 40.01 ± 17.67 years) divided into two groups: Group 1, including 86 patients with arthralgia alone (60 females; 41.15 ± 17.65 years); and Group 2, including 14 patients with concurrent arthralgia and HATMD (11 females; 33.00 ± 16.72 years). The diagnosis of TMJ arthralgia was based on the diagnostic criteria for temporomandibular disorders. The parameters of the masticatory muscles examined by ultrasonography were subjected to statistical analysis. The pain area (2.23 ± 1.75 vs. 5.79 ± 2.39, p-value = 0.002) and visual analog scale (VAS) score (3.41 ± 1.82 vs. 5.57 ± 12.14, p-value = 0.002) were significantly higher in Group 2 than in Group 1. Muscle thickness (12.58 ± 4.24 mm) and cross-sectional area (4.46 ± 2.57 cm2) were larger in the masseter muscle than in the other three masticatory muscles (p-value < 0.001). When examining sex-based differences, the thickness and area of the masseter and lower temporalis muscles were significantly larger in males (all p-value < 0.05). The area of the masseter muscle (4.67 ± 2.69 vs. 3.18 ± 0.92, p-value = 0.004) and lower temporalis muscle (3.76 ± 0.95 vs. 3.21 ± 1.02, p-value = 0.049) was significantly smaller in Group 2 than in Group 1. An increase in VAS was significantly negatively correlated with the thickness of the masseter (r =  - 0.268) and lower temporalis (r =  - 0.215), and the cross-sectional area of the masseter (r =  - 0.329) and lower temporalis (r =  - 0.293). The masseter and lower temporalis muscles were significantly thinner in females than in males, and their volumes were smaller in patients with TMJ arthralgia and HATMD than in those with TMJ arthralgia alone. HATMD and decreased masseter and lower temporalis muscle volume were associated with increased pain intensity.

Using imaging modalities to predict nanoparticle distribution and treatment efficacy in solid tumors: The growing role of ultrasound

Nanomedicine in oncology has not had the success in clinical impact that was anticipated in the early stages of the field's development. Ideally, nanomedicines selectively accumulate in tumor tissue and reduce systemic side effects compared to traditional chemotherapeutics. However, this has been more successful in preclinical animal models than in humans. The causes of this failure to translate may be related to the intra- and inter-patient heterogeneity of the tumor microenvironment. Predicting whether a patient will respond positively to treatment prior to its initiation, through evaluation of characteristics like nanoparticle extravasation and retention potential in the tumor, may be a way to improve nanomedicine success rate. While there are many potential strategies to accomplish this, prediction and patient stratification via noninvasive medical imaging may be the most efficient and specific strategy. There have been some preclinical and clinical advances in this area using MRI, CT, PET, and other modalities. An alternative approach that has not been studied as extensively is biomedical ultrasound, including techniques such as multiparametric contrast-enhanced ultrasound (mpCEUS), doppler, elastography, and super-resolution processing. Ultrasound is safe, inexpensive, noninvasive, and capable of imaging the entire tumor with high temporal and spatial resolution. In this work, we summarize the in vivo imaging tools that have been used to predict nanoparticle distribution and treatment efficacy in oncology. We emphasize ultrasound imaging and the recent developments in the field concerning CEUS. The successful implementation of an imaging strategy for prediction of nanoparticle accumulation in tumors could lead to increased clinical translation of nanomedicines, and subsequently, improved patient outcomes. This article is categorized under: Diagnostic Tools In Vivo Nanodiagnostics and Imaging Therapeutic Approaches and Drug Discovery Nanomedicine for Oncologic Disease Therapeutic Approaches and Drug Discovery Emerging Technologies.

Trends of loss of peripheral muscle thickness on ultrasonography and its relationship with outcomes among patients with sepsis

Background and aims

Data regarding trends of muscle loss on ultrasonography (USG) and its relationship with various outcomes among critically ill patients is limited. This study aimed to describe the trends of loss of muscle thickness of the arm and thigh (assessed using USG) and to determine the relationship between loss of muscle thickness and in-hospital and post-discharge outcomes.

Methods

Muscle thickness of 70 patients with sepsis was measured at the level of the mid-arm and mid-thigh using bedside USG on days 1, 3, 5, 7, 10 and 14 and then weekly till discharge or death. Patients were followed up for 90 days after discharge.

Results

The muscle thickness (mean ± SD) at the level of the mid-arm and mid-thigh on day 1 was 23.13 ± 4.83 mm and 31.21 ± 8.56 mm, respectively. The percentage muscle thickness [median (min, max)] decline at the mid-arm and mid-thigh was 7.61 (- 1.51, 32.05)% and 10.62 (- 1.48, 32.06)%, respectively on day 7 as compared to baseline (p < 0.001). The decline in muscle thickness at the mid-arm and mid-thigh were higher among non-survivors compared to survivors at all time points. Also, the decline in muscle thickness was significantly higher among patients with worse outcome at day 90. Patients with ICU-acquired weakness also had significantly higher decline in muscle thickness (p < 0.05). Early decline (from day 1 to day 3) in muscle thickness was associated with in-hospital mortality. The probability of death by day 14 was higher for patients who had early decline (from day 1 to day 3) in muscle thickness of ≥ 6.59% and ≥ 5.20% at the mid-arm [HR 7.3 (95% CI 1.5, 34.2)] and the mid-thigh [HR 8.1 (95% CI 1.7, 37.9)], respectively. Decline in thickness from day 1 to day 3 was a good predictor of in-hospital mortality with area under the curve (AUC) of 0.81 and 0.86 for arm and thigh muscles, respectively.

Conclusions

Critically ill patients with sepsis exhibit a gradual decline in muscle thickness of both the arm and thigh. Decline in muscle thickness was associated with in-hospital mortality. USG has a potential to identify patients at risk of worse in-hospital and post-discharge outcomes.

Reliability of ultrasonographic arm muscle thickness measurement by various levels of health care providers in ICU

PURPOSE

Reliability of arm muscle thickness measurement using ultrasonography (USG) by operators of varied experience is unknown. Hence, we planned this study to determine the reliability of arm muscle thickness measured using USG by 5 observers with variable experience.

MATERIALS AND METHOD

This was a cross-sectional observational study which included critically ill patients with sepsis. Arm muscle thickness was measured in triplicate on Siemens ACUSON X300™ USG machine by each of 5 observers. Intra-class correlation coefficient (ICC) was computed to assess intra-observer and inter-observer variability of multiple observations.

RESULTS

This study included 45 (30 - male) patients. Mean (±SD) age, APACHE and SAPS score of the participants were 54.95 (±15.97) years, 14.66 (±4.57) and 2.6 (±1.37), respectively. There were 135 observations by each observer. ICC (95%CI) for intra-observer reliability study for observer 1, 2, 3, 4, and 5 were 0.997 (0.995-0.998), 0.996 (0.993-0.998), 0.997 (0.996-0.998), 0.997 (0.994-0.998) and 0.998 (0.986-0.999), respectively. ICC (95%CI) for inter-observer reliability study for 1st, 2nd and 3rd reading were 0.963 (0.943-0.977), 0.992 (0.988-0.995) and 0.992 (0.988-0.995), respectively.

CONCLUSIONS

There was an excellent intra- and inter-observer agreement among 5 observers for measurement of arm muscle thickness using bedside USG among patients with sepsis.